May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Evaluation of a Novel Dry Eye Oral Supplement for the Treatment of the Signs and Symptoms of Dry Eye in the Controlled Adverse Environment (CAE) Model
Author Affiliations & Notes
  • S.G. Pratt
    Scripps Memorial Hospital, La Jolla, CA
  • G.W. Ousler
    Dry Eye Department,
    Ophthalmic Research Associates, Inc., North Andover, MA
  • M. Schindelar
    Dry Eye Department,
    Ophthalmic Research Associates, Inc., North Andover, MA
  • M.J. Chapin
    Ophthalmic Research Associates, Inc., North Andover, MA
  • M.B. Abelson
    Department of Ophthalmology, Schepens Eye Research Institute, Harvard Medical School, Boston, MA
  • Footnotes
    Commercial Relationships  S.G. Pratt, Steven Pratt P; G.W. Ousler, ORA E; M. Schindelar, ORA E; M.J. Chapin, ORA E; M.B. Abelson, ORA E.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 2047. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S.G. Pratt, G.W. Ousler, M. Schindelar, M.J. Chapin, M.B. Abelson; Evaluation of a Novel Dry Eye Oral Supplement for the Treatment of the Signs and Symptoms of Dry Eye in the Controlled Adverse Environment (CAE) Model . Invest. Ophthalmol. Vis. Sci. 2005;46(13):2047.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Abstract:
 

To evaluate the efficacy and safety of a novel Dry Eye Oral Supplement compared to a standard multivitamin in relieving the signs and symptoms of dry eye as induced by the controlled adverse environment (CAE). The use of the CAE allows for assessment before, during and following acute exacerbation of ocular signs and symptoms, allowing for a more comprehensive assessment of efficacy. This was a double–masked, randomized, controlled, parallel–group, 5–visit, single–center, CAE study evaluating signs and symptoms associated with dry eye. 24 dry eye patients entered a 3–week washout period. Following CAE screening, eligible patients were randomized to receive either the Dry Eye Oral Supplement or multi–vitamin placebo BID, in conjunction with the same standard artificial tear product TID for 10 weeks. Ophthalmic examinations and follow–up CAE challenges took place at weeks 3, 6 and 10. 23 patients completed the study. Patient reported symptom scores (0–4 on a standardized scale) during CAE exposure were compiled as follows:

 

Mean Total Discomfort during 90–Minute CAE Exposure

 

 

13 eyes (7 active, 6 placebo) presented at baseline with lid edema >0 (0–4 scale). 71% of eyes on active test article compared with no eyes on placebo, resolved completely after 10 weeks.

 

The active Dry Eye Nutritional Supplement was significantly more effective than placebo in this study for the treatment of the ocular symptoms associated with Dry Eye in the CAE. This controlled study showed that the novel Dry Eye Nutritional Supplement tested has potential for treating dry eye patient.

 

 
Keywords: cornea: tears/tear film/dry eye • cornea: clinical science 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×